[go: up one dir, main page]

DE60044503D1 - Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie - Google Patents

Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie

Info

Publication number
DE60044503D1
DE60044503D1 DE60044503T DE60044503T DE60044503D1 DE 60044503 D1 DE60044503 D1 DE 60044503D1 DE 60044503 T DE60044503 T DE 60044503T DE 60044503 T DE60044503 T DE 60044503T DE 60044503 D1 DE60044503 D1 DE 60044503D1
Authority
DE
Germany
Prior art keywords
polynucleotide
cancer
cell
antisens
gender
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044503T
Other languages
English (en)
Inventor
Masayoshi Namba
Toshiya Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60044503D1 publication Critical patent/DE60044503D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60044503T 1999-11-19 2000-08-30 Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie Expired - Lifetime DE60044503D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33060499 1999-11-19
PCT/JP2000/005879 WO2001038528A1 (fr) 1999-11-19 2000-08-30 Proteine inhibitrice de la proliferation cellulaire, polynucleotide, polynucleotide antisens de ce polynucleotide, inhibiteurs de proliferation cellulaire, diagnostics de cancers, remedes anticancereux et composition pour therapie genique les utilisant

Publications (1)

Publication Number Publication Date
DE60044503D1 true DE60044503D1 (de) 2010-07-15

Family

ID=18234524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044503T Expired - Lifetime DE60044503D1 (de) 1999-11-19 2000-08-30 Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie

Country Status (7)

Country Link
US (2) US20060275263A1 (de)
EP (1) EP1234877B1 (de)
JP (3) JP3813872B2 (de)
CN (1) CN1402784A (de)
AU (1) AU6865600A (de)
DE (1) DE60044503D1 (de)
WO (1) WO2001038528A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
EP2508606B1 (de) 2006-10-24 2017-09-13 Momotaro-Gene Inc. Teilfragment des REIC/Dkk-3-Gens und dieses enthaltendes Krebstherapeutikum
US8658612B2 (en) * 2008-07-30 2014-02-25 National University Corporation Okayama University Therapeutic agent for malignant mesothelioma and immunostimulant
TWI545196B (zh) 2011-05-25 2016-08-11 國立大學法人岡山大學 Ｒｅｉｃ表現腺病毒載體
US10782296B2 (en) 2015-09-28 2020-09-22 National University Corporation Okayama University Antibody that specifically recognizes and binds to REIC/Dkk-3 protein having active structure and monitoring of cancer treatment using such anti-REIC/Dkk-3 antibody
CA3009883C (en) 2016-01-08 2024-02-13 Momotaro-Gene Inc. A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor
WO2017217556A1 (ja) * 2016-06-17 2017-12-21 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ－３タンパク質を有効成分として含むＴＧＦβ阻害剤
JP7386553B2 (ja) 2018-11-01 2023-11-27 桃太郎源株式会社 Ａｄ－ＲＥＩＣ／Ｄｋｋ－３とチェックポイント阻害剤とを用いた胸部がんの治療のための併用療法
JP7517706B2 (ja) 2019-07-31 2024-07-17 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ－３遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法
CN116133670A (zh) 2020-07-31 2023-05-16 桃太郎源株式会社 包含REIC/Dkk-3基因的EGFR基因突变阳性肺癌的治疗药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014328A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0954575A2 (de) * 1996-12-20 1999-11-10 Human Genome Sciences, Inc. Fuer das zerebellum und embryo spezifisches protein
ATE505543T1 (de) * 1997-04-16 2011-04-15 Millennium Pharm Inc Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides

Also Published As

Publication number Publication date
US20060275263A1 (en) 2006-12-07
JP4509018B2 (ja) 2010-07-21
US20100204308A1 (en) 2010-08-12
CN1402784A (zh) 2003-03-12
WO2001038528A1 (fr) 2001-05-31
JP2010163440A (ja) 2010-07-29
EP1234877A4 (de) 2002-11-06
EP1234877B1 (de) 2010-06-02
AU6865600A (en) 2001-06-04
JP3813872B2 (ja) 2006-08-23
EP1234877A1 (de) 2002-08-28
US9243048B2 (en) 2016-01-26
JP2006158399A (ja) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE279190T1 (de) Synergistische zusammensetzungen zur krebsbehandlung
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
MXPA02000992A (es) Microarreglos y su fabricacion.
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1587837A3 (de) Epitop sequenzen abgeleited aus prostat specifischen membran antigen (psma)
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
EP1701767A4 (de) Stimulation zur behandlung und diagnose von behandlungen
EP1599420A4 (de) Abwasserbehandlungssystem
DE60044503D1 (de) Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie
EP1684758A4 (de) Verfahren und zusammensetzungen mit thalidomid zur behandlung und versorgung von krebs und anderen krankheiten
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
MXPA01011923A (es) Composiciones y metodos para tratar alteraciones en la proliferacion celular.
DK1083934T3 (da) Genterapifremgangsmåder
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
GB0722767D0 (en) Integrated biosensor and simulation system for diognosis and therapy
ZA200203166B (en) Treatment of cancer.
AU2003269378A1 (en) Methods and compositions for diagnosing and treating companion animal cancer
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
WO2002069885A9 (en) Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases
GB2419530B (en) Human prostate cell lines in cancer treatment
AU5689800A (en) Diagnosis, prognosis and treatment of cancer related to the barx2 gene
ATE286391T1 (de) Synergistische zusammensetzung zur krebsbehandlung